Nrf2 is altered in Parkinson’s and related neurodegenerative diseases, and Nrf2 activators have progressed to active clinical practice or development as neurotherapeutics [4, 53, 67–69]. This evidence concerns the gene NFE2L2 and Parkinsonism.